Onco-biome in pharmacotherapy for lung cancer: a narrative review.

ABSTRACT:

Background and objective

The gut microbiota (GM) was recently recognized to play an important role in modulating systemic immune responses and is known to influence the effects or adverse events of immune checkpoint blockade (ICB) or carcinogenesis by crosstalk with regulators of cancer-related immunity, and this relationship is complex and multifactorial. Diversity in the gut microbiome and the abundance of specific bacterial species have been identified to be associated with better response and prognosis. Therefore, the purpose of the current interest in the gut microbiome is to enable modulation of the immune system in donor cancer patients by the administration of specific bacterial species and enabling their dominance. To understand this "terra incognita" is to uncover the rol

SUBMITTER: Tateishi AT 

PROVIDER: S-EPMC9742621 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature